Subjective experiences during dopamine depletion.
de Haan
Lieuwe
L
Booij
Jan
J
Lavalye
Jules
J
van Amelsvoort
T
T
Linszen
Don
D
D000328:Adult; D001549:Benzamides; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000172:deficiency* / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced* / Q000517:prevention & control / Q000523:psychology; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000172:deficiency / Q000187:drug effects* / Q000378:metabolism; D012107:Research Design / Q000592:standards; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D019805:alpha-Methyltyrosine / Q000009:adverse effects* / Q000494:pharmacology
D001549:Benzamides; D004791:Enzyme Inhibitors; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D019805:alpha-Methyltyrosine; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D004298:Dopamine